Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.39 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939423 | 0.89 | FFAR1 (0.52) | MAOAFFAR1FFAR4 | |
| SCHEMBL938308 | 0.84 | MAOA (0.44) | MAOAFFAR1FFAR4HRH1 | |
| SCHEMBL11934944 | 0.82 | FFAR1 (0.55) | FFAR1FFAR4 | |
| SCHEMBL11131939 | 0.80 | HRH1 (0.50) | MAOAHRH1 | |
| SCHEMBL11240153 | 0.79 | SPHK1 (0.51) | CA1CA2 | |
| SCHEMBL11934940 | 0.79 | EPHX2 (0.46) | FFAR1KDM1ACA1CA2 | |
| SCHEMBL13980005 | 0.77 | HTR2A (0.52) | MAOACA1CA2HRH1 | |
| SCHEMBL938765 | 0.76 | CA1 (0.54) | MAOACA1CA2 | |
| SCHEMBL11242133 | 0.76 | S1PR1 (0.48) | CA1CA2 | |
| SCHEMBL11934716 | 0.76 | HTR2A (0.50) | FFAR1CA1CA2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1599096-B1 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1599096-A4 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1599096-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004073629-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | MAOA 1079/4885FFAR1 2253/4885PRSS1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.